On August 30^th, Zybio Inc. was recognized as the "2020 Chongqing Municipal Enterprise Technology Center" after review by the Chongqing Economic and Information Commission.

According to the "Chongqing Municipal Enterprise Technology Center Certification Management", the enterprise technology center must have a superior technology innovation mechanism and a compelete technology center organization system to clear development plans and goals, and significant innovation efficiency and results.

Zybio Inc. is a high-tech enterprise specializing in the research and development, production, sales and technical services of in vitro diagnostic reagents and instruments. There are nearly 2,500 employees worldwide, of which R&D and technical service personnel account for 1/3 of the total number, and 42% of them have a master's degree or above. In 2019, R&D investment accounted for 20.7% of the company's sales revenue. As a post-doctoral research station, Zybio continues to help promote the transformation of scientific research results. Seven R&D centers have established in Chongqing, Beijing, Shanghai, Guangzhou, Shenzhen, Nanjing and Xiamen. Our products are sold to more than 90 countries around the world.

The certification of the municipal enterprise technology center is the recognition of technological innovation mechanism and innovative development capabilities of Zybio.

The R&D product line includes chemistry, immunology, molecular, POCT, clinical examination, microbiology and raw materials, etc. Zybio has core technologies such as rapid antibody preparation, protein cross-linking, and signal amplification, and also obtained 183 product registration certificates and 37 patents of invention. In 2018, Zybio has established a standardized reference measurement laboratory, and its key projects have passed IFCC-RELA - the highest level of quality evaluation in the global clinical chemistry field.

This year, the R&D team of EXS3000, chinese first fully automated mass spectrometry system with independent intellectual property rights, has joined Zybio. The addition of more and more talents will bring Zybio continuous innovation motivation.

Zybio is keeping focusing on cutting-edge in vitro diagnostic technologies, because we are taking R&D as the core driving force for the sustainable development of company, insisting on broadening the depth and breadth of corporate development through innovation, and achieving the mission: To make diagnosis more accurate, to make life healthier.